AFT Pharmaceuticals has been granted approval by the US Food and Drug Administration (FDA) for their patented medicine Maxigesic Rapid® tablets to manage mild to moderate acute pain in the US.
The approval opens an analgesic market to AFT worth around US$7.16 billion and expected to grow by 5.8% a year.
Maxigesic Oral Liquid has also recently been approved in 12 European countries, with approval for the intravenous form of the medicine pending.
See more
